Primary Care-Based Follow-up of Cancer Survivors of the Prostate and Kidney

Prostate Cancer Clinical Trial

— LiVHOU  

Official title:

Primary Care-Based Follow-up of Cancer Survivors of the Prostate and Kidney: A Retrospective Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06214000
• Other study ID #: 8500
• Status: Completed
• Start date: December 20, 2021
• Est. completion date: June 21, 2022

Study information

• Verified date: December 2023
• Source: University Hospital, Strasbourg, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In France, the second cancer plan of 2009-2013 aimed to strengthen the role of MT by putting it back at the center of patient monitoring, in particular by asking "regional health agencies to encourage and support local experiments" which aim for better coordination between the city and the hospital. The third cancer plan for 2014-2019 insists on this measure because it had proven to be unproductive, and recommends, in addition to the creation of a nurse dedicated to the coordination of care between community medicine and the hospital, the creation of a direct telephone line to reach the hospital medical team. This measure is mainly aimed at the follow-up of certain cancers that do not require the technical support of the hospital, as is the case in the post-operative follow-up of RCC and CaP, where the additional examinations carried out during follow-up are carried out in the city.

The research hypothesis is that this new method of monitoring had a positive impact on care in terms of quality, accessibility, organization and costs.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 178
• Est. completion date: June 21, 2022
• Est. primary completion date: June 21, 2022
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult subjects (=18 years old)

• Patient operated on for localized prostate or kidney cancer

• Patient followed at the HUS during the period from 01/01/2015 to 12/31/2021

• Subject who has not expressed his opposition, after information, to the reuse of his data for the purposes of this research.

Exclusion Criteria:

• Subject having expressed opposition to participating in the study

• Patient under active therapy (hormonotherapy, systemic treatment) for the pathology studied

• Impossibility of providing the subject with informed information (difficulties in understanding the subject, etc.)

• Subject under judicial protection

• Subjects under guardianship or curatorship

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Kidney Cancer
• Kidney Neoplasms
• Prostate Cancer
• Prostatic Neoplasms

Locations

Country	Name	City	State
France	Service d'Urologie - CHU de Strasbourg - France	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of the economic impact of the treatment of patients operated on for localized prostate or kidney cancer	This study concerns a retrospective evaluation of the economic cost of treatment of localized prostate or kidney cancer in patients followed at the University Hospitals of Strasbourg during the period from January 1, 2015 to December 31, 2021.	The period concerned is from January 1, 2015 to December 31, 2021.